{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:03:25Z","timestamp":1790417005131,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":298,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Inc."}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1093\/annonc\/mdz111","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T20:44:53Z","timestamp":1553633093000},"page":"897-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"C.","family":"Ay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdz111_bb0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1093\/annonc\/mdz111_bb0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"issue":"7","key":"10.1093\/annonc\/mdz111_bb0025","doi-asserted-by":"crossref","first-page":"e1001275.","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"10","key":"10.1093\/annonc\/mdz111_bb0030","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1093\/annonc\/mdz111_bb0035","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"7","key":"10.1093\/annonc\/mdz111_bb0045","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdz111_bb0050","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"issue":"10","key":"10.1093\/annonc\/mdz111_bb0055","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"17","key":"10.1093\/annonc\/mdz111_bb0060","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"JCO"},{"issue":"10","key":"10.1093\/annonc\/mdz111_bb0065","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdz111_bb0070","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0049-3848(10)70028-1","article-title":"European Society for Medical Oncology. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management","volume":"125","author":"Mandala","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"10.1093\/annonc\/mdz111_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1093\/annonc\/mdz111_bb0080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1093\/annonc\/mdz111_bb0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0090","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"JOP"},{"issue":"10","key":"10.1093\/annonc\/mdz111_bb0095","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1093\/annonc\/mdz111_bb0100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1093\/annonc\/mdz111_bb0105","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/j.1538-7836.2006.02073.x","article-title":"Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis","volume":"4","author":"Wittkowsky","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1093\/annonc\/mdz111_bb0115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"15","key":"10.1093\/annonc\/mdz111_bb0120","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1634\/theoncologist.2011-0323","article-title":"Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer","volume":"17","author":"Delate","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1093\/annonc\/mdz111_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1093\/annonc\/mdz111_bb0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb Res"},{"key":"10.1093\/annonc\/mdz111_bb0140","first-page":"467","article-title":"Anticoagulant treatment of cancer patients with pulmonary embolism in the real world. Actual use of low-molecular-weight heparin in cancer","volume":"72","author":"Kleinjan","year":"2014","journal-title":"Neth J Med"},{"issue":"5","key":"10.1093\/annonc\/mdz111_bb0145","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE registry","volume":"82","author":"Yamashita","year":"2018","journal-title":"Circ J"},{"key":"10.1093\/annonc\/mdz111_bb0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH14-11-0977","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"Schulman","year":"2015","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1093\/annonc\/mdz111_bb0155","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1093\/annonc\/mdz111_bb0160","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1093\/annonc\/mdz111_bb0165","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1093\/annonc\/mdz111_bb0170","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0175","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1093\/annonc\/mdz111_bb0180","first-page":"916","article-title":"Clinical characteristics and treatment of patients with cancer-associated venous thromboembolism: results from the GARFIELD-VTE registry","volume":"1","author":"Weitz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1093\/annonc\/mdz111_bb0185","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdz111_bb0190","article-title":"A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer\u2014a real world experience","author":"Phelps","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1093\/annonc\/mdz111_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13074","article-title":"Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism","author":"Simmons","year":"2018","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1093\/annonc\/mdz111_bb0200","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1078155217718382","article-title":"Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: the Re-CLOT study","volume":"24","author":"Alzghari","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1093\/annonc\/mdz111_bb0205","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"Ianotto","year":"2017","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1093\/annonc\/mdz111_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1078155217690922","article-title":"Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin","volume":"24","author":"Nicklaus","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1093\/annonc\/mdz111_bb0215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1078155217726158","article-title":"Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer","volume":"25","author":"Pritchard","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1093\/annonc\/mdz111_bb0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","article-title":"Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis","volume":"150","author":"Ross","year":"2017","journal-title":"Thromb Res"},{"key":"10.1093\/annonc\/mdz111_bb0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","volume":"25","author":"Uppuluri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1093\/annonc\/mdz111_bb0230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"issue":"7","key":"10.1093\/annonc\/mdz111_bb0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1093\/annonc\/mdz111_bb0240","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"JCO"},{"key":"10.1093\/annonc\/mdz111_bb0245","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO); https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03045406 (9 July 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdz111_bb0250","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1093\/annonc\/mdz111_bb0255","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1093\/annonc\/mdz111_bb0260","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2018-99-118808","article-title":"Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial","volume":"132","author":"McBane","year":"2018","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdz111_bb0265","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients; https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02583191 (11 July 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdz111_bb0270","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. Direct oral anticoagulants (DOACs) versus LMWH +\/- warfarin for VTE in cancer (CANVAS); https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02744092 (11 July 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdz111_bb0275","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1093\/annonc\/mdz111_bb0280","unstructured":"PRADAXA\u00ae (Dabigatran Etexilate Mesylate) Capsules, for Oral Use. Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 2015."},{"key":"10.1093\/annonc\/mdz111_bb0285","unstructured":"SAVAYSA\u00ae (Edoxaban) Tablets, for Oral Use. Full Prescribing Information. Daiichi Sankyo, Inc., Parsippany, NJ, USA 2015."},{"key":"10.1093\/annonc\/mdz111_bb0290","unstructured":"XARELTO\u00ae (Rivaroxaban) Tablets, for Oral Use. Full Prescribing Information. Janssen Pharmaceuticals, Inc., Titusville, NJ, USA 2016."},{"key":"10.1093\/annonc\/mdz111_bb0295","unstructured":"ELIQUIS\u00ae (Apixaban) Tablets, for Oral Use. Full Prescribing Information. Bristol-Myers Squibb Company, Princeton, NJ, USA 2016."},{"issue":"17","key":"10.1093\/annonc\/mdz111_bb0300","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"JCO"},{"issue":"6","key":"10.1093\/annonc\/mdz111_bb0305","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1093\/annonc\/mdz111_bb0310","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2018.09.015","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions","volume":"132","author":"Riess","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1093\/annonc\/mdz111_bb0315","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"issue":"16","key":"10.1093\/annonc\/mdz111_bb0320","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1093\/annonc\/mdz111_bb0325","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdz111_bb0330","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. Drug interaction study of Apixaban with Cyclosporine and Tacrolimus (ACT); https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03083782 (16 July 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdz111_bb0335","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. A pilot study investigating Apixaban and Dexamethasone interAction in Multiple myeloma (ADAM); https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02749617 (16 July 2018, date last accessed)."},{"issue":"9","key":"10.1093\/annonc\/mdz111_bb0340","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1093\/annonc\/mdz111_bb0345","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Cancer-Associated Venous Thromboembolic Disease. Version 2.2018\u2014August 27, 2018; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf (24 September 2018, date last accessed)."},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdz111_bb0350","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.thromres.2018.01.002","article-title":"Overview of VTE treatment in cancer according to clinical guidelines","volume":"164","author":"Lee","year":"2018","journal-title":"Thromb Res"},{"issue":"5","key":"10.1093\/annonc\/mdz111_bb0355","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jth.13659","article-title":"Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant","volume":"15","author":"Elalamy","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1093\/annonc\/mdz111_bb0360","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.12725","article-title":"Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH","volume":"12","author":"Khorana","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1093\/annonc\/mdz111_bb0365","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdz111_bb0370","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz111\/28566135\/mdz111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz111\/28566857\/mdz111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/6\/897\/28871783\/mdz111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:06:34Z","timestamp":1668711994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419312049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0923753419312049"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz111","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}